Efficacy and safety of once‐weekly semaglutide 2.4 mg for weight management in participants from China: A prespecified analysis of the STEP 7 randomized clinical trial
Primary result · Percentage change in body weightResult — go to the resultEstimated treatment difference −8.3 % 95% CI −10.2 to −6.4Authors' conclusion
These data demonstrate beneficial effects of semaglutide 2.4 mg versus placebo, supporting its use in an adult Chinese population with overweight or obesity.
Study context
- Population
- Chinese adults with overweight or obesity, with or without T2D, from STEP 7
- Participants
- 195 vs 105
- Comparison
- Once-weekly SC semaglutide 2.4 mg vs placebo, adjunct to reduced-calorie diet and increased physical activity
- Semaglutide 2.4 mgn = 195
- Placebon = 105reference
- Primary endpoint
- Percentage change in body weight; proportion achieving ≥5% body weight reduction
- Follow-up
- Baseline to Week 44
Methodological detailsdouble-blind, phase 3a, randomized 2:1
- Double-blind
- Phase 3a
- Randomized 2:1
Primary result
Percentage change in body weight · Week 44
Estimated treatment difference
−8.3 %
95% CI −10.2 to −6.4
P < 0.0001
Change by group
Semaglutide 2.4 mg
−11.8
mean · %
Placebo
−3.5
mean · %
Semaglutide 2.4 mgvs Placebo
estimated treatment difference −8.3 % (95% CI −10.2 to −6.4); P < 0.0001
As reported in the abstract
Further findings
| Outcome | Semaglutide 2.4 mg | Placebo | OR (95% CI) | P value | |
|---|---|---|---|---|---|
| ≥5% body weight loss (co-primary endpoint) · Week 44 | 85.4% | 26.8% | 16.1 (8.4–30.9) | P < 0.0001 | |
| 0.050.21520Odds ratio (log scale) |
Safety
Adverse events
Gastrointestinal disorders (most common AEs)
Original publication
Efficacy and safety of once‐weekly semaglutide 2.4 mg for weight management in participants from China: A prespecified analysis of the STEP 7 randomized clinical trial. Diabetes Obes Metab. Published 11 March 2025. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →